• The Conference on Retroviruses and Opportunistic Infections (CROI) 2025 will convene in San Francisco from March 9-12, featuring cutting-edge research on HIV cure strategies, COVID-19 variants, and viral infections.
• Late-breaking sessions will present phase III clinical trials of novel antivirals, including ensitrelvir for COVID-19 prevention and doravirine/islatravir for HIV treatment.
• The conference will address critical public health initiatives, including HIV self-testing programs, doxycycline post-exposure prophylaxis (doxyPEP), and machine learning applications in HIV care management.